Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine
November 29 2020 - 9:07PM
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening
Reach to Hematologic Cancers and Transplant Medicine
Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’)
announces it has entered into an agreement with Scintec Diagnostics
GmbH (‘Scintec’) to acquire TheraPharm GmbH (‘TheraPharm’), a
Swiss-German biotechnology company developing innovative diagnostic
and therapeutic solutions in the field of hematology.
The acquisition of TheraPharm provides Telix
with access to a portfolio of patents, technologies, production
systems, clinical data and know-how in relation to the use of
Molecularly Targeted Radiation (MTR) in hematology and immunology.
TheraPharm is developing antibody MTR technology against CD66, a
cell surface target highly expressed by neutrophils (a type of
white blood cell) and tumor-infiltrating lymphocytes. As such, the
technology has potentially very broad applications in the diagnosis
and treatment of hematologic diseases (e.g. blood cancers),
lymphoproliferative disorders and immune-mediated diseases (e.g.
lupus, and multiple sclerosis). Of particular interest is the
demonstrated use of the technology to safely and effectively
perform bone marrow conditioning (BMC) prior to bone marrow stem
cell transplant.
Telix CEO, Dr. Christian Behrenbruch stated,
“Telix is committed to extending and improving the lives of
patients with serious diseases. As such, the acquisition of
TheraPharm and its MTR assets are uniquely aligned to Telix’s
mission and technical strengths in antibody engineering and
radiochemistry. TheraPharm’s technology has a significant role to
play in BMC and stem cell transplantation across a broad range of
blood cancers and rare diseases. The current approach to BMC
employs highly toxic drugs that have a poor morbidity and mortality
profile, and for which many patients are ineligible. MTR offers an
excellent safety profile that may greatly expand the number of
patients able to undergo life prolonging stem cell transplantation
while greatly reducing the hospitalisation burden and cost
associated with such procedures.”
TheraPharm co-founder and Managing Director, Dr.
Klaus Bosslet added, “Over the past 5 years, TheraPharm, in
collaboration with Dr. Kim Orchard from the University of
Southampton (UK), has made excellent progress developing
90Y-besilesomab for the treatment of hematologic cancers and
several related conditions including multiple myeloma, leukemia and
amyloidosis. This unique asset is a logical addition to Telix’s
portfolio, offering a potentially rapid development path to a first
commercial indication for the treatment of patients with SALA,
while at the same time having potentially broad applications for
stem cell transplantation in patients with more common cancers of
the blood, including multiple myeloma and leukemia. We look forward
to joining the Telix team in order to expedite the development of
products for this under-served field.”
Full transaction details, including financial
terms, can be found via the Telix website and ASX portal here.
About
Hematopoietic Stem Cell Transplant
(HSCT)
Bone marrow conditioning (BMC) followed by
hematopoietic stem cell transplantation (HSCT) is presently
performed to treat patients with hematologic malignancies (blood
cancers), with the objective of extending patient survival or
achieving cure. HSCT is also performed for a broad range of
non-cancer conditions. HSCT is preferentially performed in
countries of high income (Europe >30,000, Americas >20,000,
worldwide >65,000 p.a., respectively) and is growing at around
5% annually.
About Systemic Amyloid
Light-Chain Amyloidosis (SALA)
SALA is a rare, but serious protein deposition
disease, caused by a protein known as ‘amyloid’ that is produced by
abnormal plasma cells residing in the bone marrow. As amyloid
accumulates in the organs of the body, organ function will
eventually deteriorate, ultimately causing organ failure. SALA has
an estimated prevalence of 30,000 and 45,000 in United States and
Europe, respectively and while a rare disease, SALA portends a very
poor prognosis, with a median survival from diagnosis of ~11 months
if untreated.
The current standard of care comprises of
induction therapy (typically cyclophosphamide, bortezomib,
dexamethasone) plus high dose melphalan BMC, followed by HSCT. This
approach is typically only accessible to a small proportion of
patients (<20%) who are able to tolerate induction therapy and
melphalan BMC.
About Telix Pharmaceuticals
Limited
Telix is a clinical-stage biopharmaceutical
company focused on the development of diagnostic and therapeutic
products using Molecularly Targeted Radiation (MTR). Telix is
headquartered in Melbourne, Australia with international operations
in Belgium, Japan and the United States. Telix is developing a
portfolio of clinical-stage oncology products that address
significant unmet medical needs in prostate, kidney and brain
cancer. Telix is listed on the Australian Securities Exchange (ASX:
TLX). For more information visit www.telixpharma.com.
About
TheraPharm GmbH
TheraPharm is a biotechnology company
specialised in the research, development and manufacturing of
monoclonal antibodies for targeted radiation of hematopoietic
malignant and non-malignant diseases, lymphoproliferative diseases,
conditioning for allogeneic stem cells as well as in diagnostics of
inflammatory diseases and bone marrow metastases.
Telix Corporate Contact |
Telix Investor Relations |
Dr. Christian Behrenbruch |
Dr. David N. Cade |
Telix Pharmaceuticals Limited |
Telix Pharmaceuticals Limited |
CEO |
CBO and Head of Investor Relations |
Email: Christian@telixpharma.com |
Email: david.cade@telixpharma.com |
Telix Pharmaceuticals (ASX:TLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Telix Pharmaceuticals (ASX:TLX)
Historical Stock Chart
From Sep 2023 to Sep 2024